By Maria Ruiz, RD · Reviewed by Dr. Elena Santos, MD · Last reviewed: May 15, 2026
GLP-1 vs Bariatric Surgery: A Side-by-Side Decision Guide
Two paths to major weight loss. Both proven. Both with trade-offs. This guide pulls the numbers from the American Society for Metabolic and Bariatric Surgery (ASMBS), the American Gastroenterological Association (AGA), the FDA labels for Wegovy and Zepbound, and the published STEP and SURMOUNT trials.
GLP-1 vs Bariatric Surgery: Quick Comparison
| Factor | GLP-1 (Wegovy / Zepbound) | Bariatric Surgery (RYGB / Sleeve) |
|---|---|---|
| Average weight loss at 1 year | 12 to 18% (per STEP and SURMOUNT) | 25 to 30% (per ASMBS data) |
| Eligibility (BMI) | 30+, or 27+ with comorbidity | 35+, or 30 to 34.9 with comorbidity |
| Cost without insurance | $800 to $1,500 per month | $15,000 to $25,000 one-time |
| Cost with good insurance | $0 to $25 per month | Mostly covered, plus copays |
| Recovery time | 0 days | 4 to 6 weeks |
| Treatment type | Chronic, ongoing | One-time procedure |
| Weight regain if stopped | Two-thirds within 1 year | 5 to 20% over years |
| Procedural risk | None (drug side effects only) | 0.1 to 0.3% mortality |
| Lifetime follow-up | Quarterly check-ins | Annual visits plus supplements |
| Best for | Lower BMI, prefers reversible | Higher BMI, can afford one-time |
Sources: ASMBS 2022 Indications for Metabolic and Bariatric Surgery, FDA Prescribing Information for Wegovy and Zepbound, STEP-1 (Wilding et al., NEJM 2021), SURMOUNT-1 (Jastreboff et al., NEJM 2022).
Efficacy: How Much Weight Will I Lose?
The trial data tells a clear story.
- • STEP-1 (semaglutide 2.4 mg): 14.9% mean weight loss at 68 weeks
- • SURMOUNT-1 (tirzepatide 15 mg): 22.5% mean weight loss at 72 weeks
- • ASMBS data on Roux-en-Y gastric bypass: 25 to 30% at 1 year, holding 20 to 25% at 5 years
- • ASMBS data on sleeve gastrectomy: 20 to 25% at 1 year, holding 15 to 20% at 5 years
Bariatric surgery still leads on average weight loss, especially at the 5-year mark. But the gap is the smallest it has ever been. Tirzepatide comes within 5 to 10 percentage points of surgery for many patients.
Eligibility: Do I Qualify?
Eligibility rules changed for both paths in the last few years.
GLP-1 eligibility (per FDA labels):
- • BMI 30 or higher (obesity), or
- • BMI 27 or higher with at least one weight-related comorbidity (T2D, high blood pressure, high cholesterol, sleep apnea, fatty liver disease)
Bariatric surgery eligibility (per ASMBS 2022):
- • BMI 35 or higher (no comorbidity needed), or
- • BMI 30 to 34.9 with a metabolic disease (especially T2D)
- • Many surgeons want documented prior weight loss attempts
- • Most insurers require a 3 to 6 month pre-op program
Cost: The 5-Year Math
Cost is the biggest practical factor for most patients.
- • GLP-1 without insurance over 5 years: $48,000 to $90,000
- • GLP-1 with insurance (typical copay) over 5 years: $1,500 to $7,500
- • Bariatric surgery without insurance: $15,000 to $25,000 one-time + $500 to $2,000 yearly follow-up
- • Bariatric surgery with insurance: $1,000 to $5,000 total out-of-pocket
If your insurance covers GLP-1, the drug is far cheaper than surgery. If your insurance does not cover GLP-1 and you need long-term treatment, surgery is the cheaper long-term path. Check your plan carefully.
Recovery and Lifestyle Impact
GLP-1 has no procedural recovery. You take a weekly shot. You eat smaller portions. You may have nausea or fatigue for the first 4 to 8 weeks. You work, drive, exercise, and live a normal life.
Bariatric surgery is real surgery. Per ASMBS, the typical recovery is 1 to 2 weeks for desk work, 4 to 6 weeks for full activity. The first 3 months are a phased diet from clear liquids up to regular food. You need lifetime vitamin supplements and annual labs. Many patients also deal with dumping syndrome, food intolerances, and skin changes.
A Simple Decision Framework
Bariatric surgery may be a better fit if:
- • Your BMI is 40 or higher
- • You have severe T2D, sleep apnea, or fatty liver disease
- • You cannot afford GLP-1 long term
- • You want a one-time solution and can commit to lifelong vitamins
- • You have failed years of medical weight loss attempts
GLP-1 may be a better fit if:
- • Your BMI is 27 to 39
- • Your insurance covers Wegovy or Zepbound
- • You want a reversible option
- • You cannot or do not want to take time off work for surgery
- • You prefer a slower, steady weight loss curve
Next Step: Get a Real Answer
The fastest path to a real answer is a telehealth GLP-1 consult plus a bariatric surgical consult. Both are low cost and low commitment.
For bariatric surgery, ask your primary care doctor for a referral to an ASMBS-accredited center.
Related guides
- Teladoc vs Ro vs Hims for GLP-1 - compare 3 telehealth GLP-1 paths
- GLP-1 meal prep cost comparison - meal-prep budget on a GLP-1
- Side effects management - nausea, constipation, fatigue
- Full GLP-1 diet guide - macros and food rules
Frequently Asked Questions
Which loses more weight, GLP-1 or bariatric surgery?
Bariatric surgery still wins on average weight loss. Per published trial data, Roux-en-Y gastric bypass produces 25 to 30 percent total body weight loss at 1 year. The SURMOUNT-1 trial of tirzepatide showed 22.5 percent at 72 weeks for the 15 mg dose. The STEP-1 trial of semaglutide showed 14.9 percent at 68 weeks. Surgery still leads at the population level, but GLP-1 drugs have closed the gap a lot.
Who is eligible for bariatric surgery?
Per the American Society for Metabolic and Bariatric Surgery (ASMBS) 2022 guidelines, the cut-off is BMI 35 or higher (no comorbidity needed) or BMI 30 to 34.9 with a metabolic disease like type 2 diabetes. This is a recent update. The older rule was BMI 40 or BMI 35 with a comorbidity. Eligibility now starts earlier than most people realize.
Who is eligible for a GLP-1 drug for weight loss?
Per the FDA labels for Wegovy and Zepbound, eligibility is BMI 30 or higher, or BMI 27 with at least one weight-related comorbidity (high blood pressure, high cholesterol, type 2 diabetes, sleep apnea). This is a lower bar than surgery. More people qualify for GLP-1 than for surgery.
How much does bariatric surgery cost?
Out-of-pocket bariatric surgery costs $15,000 to $25,000 in the United States. The ASMBS surgeon network reports a median of about $20,000 for Roux-en-Y gastric bypass and $17,000 for sleeve gastrectomy. Many insurance plans now cover it under obesity treatment, but plans require documented weight loss attempts first and pre-approval. Add follow-up costs of $500 to $2,000 per year.
How much do GLP-1 drugs cost?
Without insurance, Wegovy and Zepbound list at $1,000 to $1,500 per month in 2026. With manufacturer savings cards and commercial insurance, many patients pay $0 to $25 per month. Without coverage, expect $800 to $1,500 monthly. Over 5 years, that is $48,000 to $90,000. Bariatric surgery becomes the cheaper option if you cannot get insurance coverage for the GLP-1.
What is the recovery time for bariatric surgery?
Most patients return to desk work in 1 to 2 weeks and to full activity in 4 to 6 weeks. Per ASMBS, the first 3 months are a phased diet (clear liquids, then full liquids, then pureed, then soft solids, then regular). Lifetime supplements and follow-ups are required. GLP-1 drugs have no procedural recovery. You take the shot and continue normal life.
What happens if I stop the GLP-1?
Per the STEP-4 trial published in JAMA, patients who stopped semaglutide regained about two-thirds of the lost weight within a year. Per the SURMOUNT-4 trial, tirzepatide showed a similar regain pattern. GLP-1 is chronic therapy. If you stop, weight returns. Bariatric surgery is one-time but requires lifetime food and supplement habits to maintain.
What are the risks of bariatric surgery vs GLP-1?
Bariatric surgery has a 0.1 to 0.3 percent 30-day mortality risk per ASMBS data. Surgical risks include leaks, bleeding, infection, and long-term issues like dumping syndrome, vitamin deficiencies, and gallstones. GLP-1 drugs carry a boxed warning for thyroid C-cell tumors and warnings for acute pancreatitis, gallbladder disease, low blood sugar (with insulin or sulfonylureas), and kidney problems from dehydration. Both paths have real risks. Both need a qualified medical team.
Primary Sources
- American Society for Metabolic and Bariatric Surgery (ASMBS). 2022 Indications for Metabolic and Bariatric Surgery.
- American Gastroenterological Association (AGA). Clinical Practice Guideline on Pharmacological Interventions for Adults with Obesity. Gastroenterology, 2022.
- FDA. Wegovy (semaglutide) Prescribing Information. Novo Nordisk.
- FDA. Zepbound (tirzepatide) Prescribing Information. Eli Lilly.
- STEP-1 trial. Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021.
- STEP-4 trial. Rubino et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA, 2021.
- SURMOUNT-1 trial. Jastreboff et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 2022.
- SURMOUNT-4 trial. Aronne et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity. JAMA, 2024.